Drug profile · INN
deferasirox
DEFERASIROX JUNO
deferasirox (DEFERASIROX JUNO) is a iron chelating agent. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — deferasirox
- US status
- approved
- Class
- Various (V03)
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
deferasirox (DEFERASIROX JUNO) is a iron chelating agent. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Iron chelating agent
Primary target: Iron
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is deferasirox?
deferasirox (DEFERASIROX JUNO) is a iron chelating agent. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for deferasirox?
DEFERASIROX JUNO is a marketed brand name for deferasirox. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of deferasirox?
deferasirox has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.